By Fineline Cube 
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi healthcare products company. The collaboration involves an exclusive supply and distribution agreement for Zhaoke’s self-developed cyclosporine eye gel, a dry eye treatment.
Distribution Agreement
Under the terms of the agreement, Zhaoke Ophthalmology grants Jamjoom Pharma exclusive distribution rights for the product across several Middle Eastern countries, including Saudi Arabia, UAE, Bahrain, Kuwait, Oman, and Qatar. Jamjoom Pharma will take charge of obtaining drug registrations in these regions on behalf of Zhaoke and will be responsible for the exclusive import, promotion, distribution, marketing, and sale of the cyclosporine ophthalmic gel.
Milestone Payments
Zhaoke Ophthalmology will receive specified payments upon achieving certain milestones as outlined in the agreement.
Regulatory and Market Expansion
The product, which is awaiting regulatory decisions in China, received clinical approval from the U.S. FDA last month. This marks a significant step forward in its internationalization process. This partnership represents Zhaoke Ophthalmology’s first out-licensing of a self-developed innovative ophthalmic drug and is a notable milestone in the company’s global expansion strategy.-Fineline Info & Tech